Emergent BioSolutions (EBS) completed the sale of its Baltimore-Bayview drug substance manufacturing facility in Maryland to India's Syngene International for $36.5 million.
The sale covers the facility's assets and equipment, Emergent said Wednesday in a statement.
Emergent retains the option to access manufacturing services and capacity at the site to support future growth and pandemic response efforts in partnership with Syngene.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments